SCHEMBL5333315

SCHEMBL5333315

O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1Br

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCB P05771 9/20 0.78
CDK4 P11802 3/20 0.78
CCND1 P24385 3/20 0.78
CDK2 P24941 3/20 0.78
PRKCA P17252 2/20 0.78
CAMK2D Q13557 2/20 0.78
CCNE2 O96020 2/20 0.78
PRKACA P17612 2/20 0.78
PRKACG P22612 2/20 0.78
PRKACB P22694 2/20 0.78
CCNE1 P24864 2/20 0.78
SIRT2 Q8IXJ6 2/20 0.78
ABL1 P00519 2/20 0.78
PRKD3 O94806 1/20 0.78
CCNB2 O95067 1/20 0.78
PRKCG P05129 1/20 0.78
CDK1 P06493 1/20 0.78
PIM1 P11309 1/20 0.78
CCNB1 P14635 1/20 0.78
PRKCH P24723 1/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29756414 1.00 PRKCB (0.78) PRKCBCDK4CCND1CDK2PRKCA
Ro-316233 SCHEMBL29373011 0.88 PRKCB (1.00) PRKCBCDK4CCND1CDK2PRKCA
Ro-316233 SCHEMBL624896 0.88 PRKCB (1.00) PRKCBCDK4CCND1CDK2PRKCA
SCHEMBL7822950 0.82 PRKCB (0.74) PRKCBCDK4CCND1CDK2PRKCA
SCHEMBL9085566 0.82 CDK4 (0.74) PRKCBCDK4CCND1CDK2PRKCA
SCHEMBL9086205 0.81 PRKCB (0.72) PRKCBCDK4CCND1CDK2PRKCA
SCHEMBL9085668 0.81 PRKCB (0.72) PRKCBCDK4CCND1CDK2PRKCA
SCHEMBL3148490 0.81 PRKCB (0.84) PRKCBCDK4CCND1CDK2PRKCA
SCHEMBL3908534 0.81 PRKCB (0.78) PRKCBCDK4CCND1CDK2PRKCA
SCHEMBL13917970 0.81 PRKCB (0.78) PRKCBCDK4CCND1CDK2PRKCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004083202-A1 A PROCESS FOR THE PREPARATION OF INDOLYMALEIMIDES SUVEN LIFE SCIENCES LIMITED (IN) 2004-09-30 WO claimed
EP-3805214-B1 JAK3 SELECTIVE INHIBITOR UNIV PEKING SHENZHEN GRADUATE SCHOOL (CN) 2023-07-05 EP disclosed
EP-3805214-A1 JAK3 SELECTIVE INHIBITOR Peking University Shenzhen Graduate School (CN) 2021-04-14 EP disclosed
WO-2019228442-A1 JAK3 SELECTIVE INHIBITOR 北京大学深圳研究生院 (CN) 2019-12-05 WO disclosed
US-7202255-B2 Substituted [1,4] benzodioxino[2,3-e] isoindole derivatives, method for preparing and pharmaceutical compositions containing same LES LABORATOIRES SERVIER (FR) 2007-04-10 US disclosed
EP-1587810-B1 NOVEL SUBSTITUTED 1,4|BENZODIOXINO 2,3-E|ISOINDOLE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SERVIER LAB (FR) 2006-11-08 EP disclosed
US-20060040930-A1 Novel substituted [1,4] benzodioxino[2,3-e] isoindole derivatives, method for preparing and pharmaceutical compositions containing same LES LABORATOIRES SERVIER (FR) 2006-02-23 US disclosed
WO-2004083202-A1 A PROCESS FOR THE PREPARATION OF INDOLYMALEIMIDES SUVEN LIFE SCIENCES LIMITED (IN) 2004-09-30 WO disclosed
EP-0397060-B1 Maleinimide derivatives and their use as medicines GOEDECKE AG (DE) 2001-11-21 EP disclosed
US-RE36736-E Substituted pyrroles HOFFMAN-LA ROCHE INC. (US) 2000-06-13 US disclosed
US-5516915-A Bis-(1H-indol-3-yl)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them GOEDECKE AKTIENGESELLSCHAFT (DE) 1996-05-14 US disclosed
US-5380746-A Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them GOEDECKE AKTIENGESELLSCHAFT (DE) 1995-01-10 US disclosed
EP-0328026-B1 SUBSTITUTED PYRROLES F. HOFFMANN-LA ROCHE AG (CH) 1993-04-28 EP disclosed
US-5057614-A Antiinflammatory, immunology, bronchodilator agents, cardiovascular disorders HOFFMANN-LA ROCHE INC. (US) 1991-10-15 US disclosed
EP-0397060-A2 Maleinimide derivatives and their use as medicines GÖDECKE AKTIENGESELLSCHAFT (DE) 1990-11-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040930-A1 Novel substituted [1,4] benzodioxino[2,3-e] isoindole derivatives, method for preparing and pharmaceutical compositions containing same CYP11B2, CYP2F1, CYP3A43 PRKCB 3888/4885CDK4 1647/4885CCND1 838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.